Welcome to our dedicated page for Atea Pharmaceuticals news (Ticker: AVIR), a resource for investors and traders seeking the latest updates and insights on Atea Pharmaceuticals stock.
Atea Pharmaceuticals, Inc. (AVIR) is a clinical-stage biopharmaceutical company pioneering oral antiviral therapies for severe viral diseases. This page provides investors and healthcare professionals with timely updates on clinical trial progress, regulatory milestones, and corporate developments.
Key resources include: Press releases detailing study results, partnership announcements with research institutions, and financial disclosures. Track updates on COVID-19 therapeutic candidates, hepatitis C treatments, and emerging programs targeting RNA viruses.
All content is sourced directly from company filings and official communications to ensure accuracy. Visitors can expect detailed coverage of Phase 2/3 trial outcomes, FDA interactions, and strategic initiatives advancing antiviral drug development.
Bookmark this page for consolidated access to AVIR's latest scientific advancements and business updates. Check regularly for new developments from Atea's nucleos(t)ide prodrug platform and pipeline expansion efforts.
Atea Pharmaceuticals (AVIR) provided updates on AT-752, an oral antiviral for dengue fever, during the ASTMH 2022 Annual Meeting. The Phase 1 trial showed that AT-752 was well tolerated at doses up to 1500 mg, achieving plasma levels above the in vitro EC90. The FDA has given Fast Track designation for AT-752, making it a promising option for treating dengue, which affects 400 million annually. Atea is advancing two proof-of-concept studies to evaluate AT-752's safety and efficacy against dengue, aiming to fill the existing treatment gap.
Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) will host a live conference call on November 7, 2022, at 4:30 p.m. ET, to report financial results for Q3 2022 and provide a business update. The call can be accessed via registration, with a webcast available in the Investor Relations section of the company's website. Atea focuses on developing oral therapies for severe diseases, particularly targeting ssRNA viruses, including SARS-CoV-2, HCV, dengue, and RSV. The company aims to expand its antiviral pipeline through its proprietary nucleos(t)ide prodrug platform.
Atea Pharmaceuticals (Nasdaq: AVIR) announced that the FDA granted Fast Track Designation to AT-752, an oral antiviral for dengue treatment. This designation aims to expedite development, acknowledging the urgent need for effective treatments as there are currently no approved options. AT-752 has shown promising preclinical activity against dengue and safety in Phase 1 trials. The company is advancing two Phase 2 studies to assess AT-752’s efficacy and safety in adults with dengue virus infections, with initial data expected soon.
Atea Pharmaceuticals (Nasdaq: AVIR) announced a global Phase 3 trial to assess bemnifosbuvir for COVID-19, beginning in Q4 2022. The trial targets high-risk non-hospitalized patients, evaluating bemnifosbuvir as both monotherapy and in combination with other treatments. Previous trials indicated a 71% reduction in hospitalization rates. The randomized, double-blind study aims to enroll 1,500 patients across 300 sites worldwide, focusing on safety and efficacy against various COVID-19 variants. Positive early results emphasize bemnifosbuvir's potential as a cornerstone therapy for COVID-19 treatment.
Atea Pharmaceuticals (Nasdaq: AVIR) announced participation in key investor events on September 13, 2022. The management will host a conference call at 8:30 a.m. ET to detail the global Phase 3 trial of bemnifosbuvir for COVID-19 treatment. Additionally, CEO Jean-Pierre Sommadossi will engage in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference at 12:55 p.m. ET. Live webcasts of these events will be available on Atea's website.
Atea Pharmaceuticals (AVIR) is advancing bemnifosbuvir into late-stage clinical trials for COVID-19 after discussions with the FDA and EMA. New data show bemnifosbuvir retains antiviral activity against the Omicron variant. The company is also enrolling in Phase 2 trials for dengue and preparing for a Phase 2 trial for HCV. Financially, Atea reported a net loss of $31.3 million for Q2 2022, a significant drop from a net income of $1.5 million in Q2 2021, driven by the loss of collaboration revenue from Roche.
Atea Pharmaceuticals (AVIR) announced a live conference call for August 8, 2022, at 4:30 p.m. ET to discuss its Q2 financial results and provide a business update. The company focuses on developing oral antiviral therapies for severe viral diseases, including COVID-19 and hepatitis C. This event will be accessible via registration and a live webcast on their investor relations website. Atea emphasizes its commitment to advancing its nucleos(t)ide prodrug platform for treating RNA viruses. They also caution about risks associated with forward-looking statements.
Atea Pharmaceuticals (Nasdaq: AVIR) announced participation in the William Blair Biotech Focus Conference, with a pre-recorded fireside chat available from July 11, 2022, at 9:00 a.m. ET. The company focuses on developing oral antiviral therapies for severe diseases, utilizing its proprietary nucleos(t)ide prodrug platform. Current efforts include treatments for COVID-19, hepatitis C, dengue, and RSV. Atea emphasizes its commitment to advancing antiviral candidates through ongoing research and development.
Atea Pharmaceuticals (Nasdaq: AVIR) announced that CEO Jean-Pierre Sommadossi will present a corporate overview at the Jefferies Healthcare Conference on June 8, 2022, at 11:00 a.m. ET. A live webcast will be accessible on their website, and a replay will be available for 90 days. Atea is a clinical-stage biopharmaceutical company focused on developing oral antiviral therapies for serious diseases, including COVID-19 and HCV, utilizing its proprietary nucleos(t)ide prodrug platform. The company emphasizes its commitment to addressing unmet medical needs in severe viral infections.
Atea Pharmaceuticals (AVIR) announced new clinical results from the MORNINGSKY trial, indicating a 71% reduction in hospitalization for COVID-19 patients treated with bemnifosbuvir (AT-527) compared to placebo (p=0.047). The Phase 2 study in high-risk patients also showed no deaths among those treated with bemnifosbuvir. The company initiated a Phase 2 global study for AT-752 targeting dengue and is preparing for a combination study of bemnifosbuvir and ruzasvir for hepatitis C in 2H 2022. Atea reported a net loss of $42.1 million for Q1 2022.
FAQ
What is the current stock price of Atea Pharmaceuticals (AVIR)?
What is the market cap of Atea Pharmaceuticals (AVIR)?
